Company Announcement

Nykode Therapeutics to Present and Participate in Fireside Chat at the 17th DNB Carnegie Nordic Healthcare Conference

Oslo, Norway, November 20, 2026 — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, today announced that its CEO, Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate in the 17th DNB Carnegie Nordic Healthcare Conference on Tuesday, November 24, 2026, in Oslo, Norway. The company's participation will include a company presentation and fireside chat.

Presentation Details

Presenter: Michael Engsig & Agnete Fredriksen
Date: Tuesday, November 24, 2026
Time: 2:45–3:05 p.m. CET
Location: Auditorium 3

The presentation and fireside chat will provide an opportunity to discuss Nykode's recent progress and key developments across its pipeline, including abi-suva, its lead program in the Phase 2 Abili-T trial, and VB10.NEO, its individualized neoantigen cancer vaccine, as well as the company's immune tolerance platform.

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidate is abi-suva, a cancer vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027. VB10.NEO, an individualized cancer vaccine, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway